ArticleClinical parkinsonism & related disorders2025
Effects of dopaminergic medication on upper limb motor function, strength and hand dexterity in people with Parkinson's disease.
Article in Clinical parkinsonism & related disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dopaminergic medications improve motor symptoms and hand dexterity in people with Parkinson's disease (PD). The contribution of altered muscle contractile properties to these functional improvements are not well understood. Objective: To compare the treated (ON) and untreated (OFF) states in people with PD to examine effects of dopaminergic medication on hand dexterity, motor symptom severity, muscle twitch properties and maximal voluntary contraction (MVC). Methods: Sixteen individuals with PD (mean disease duration 6.4 years) completed two sessions: one ON and one OFF dopaminergic medication. Measures included motor symptom severity (MDS-UPDRS III), Grooved Pegboard Test (GPT) time, Purdue Pegboard Test (PPT) peg count, elbow flexion MVC, voluntary activation, and electrically induced twitch properties. Results: MDS-UPDRS III subscores improved by 27 % ON dopaminergic medication compared to OFF medication, and performance improved on GPT (11 %) and PPT (34 %; p < 0.05). Comparing ON and OFF states, electrically induced contractile properties did not differ, while voluntary elbow flexor MVC increased by 4 %. Normalized MVC was moderately associated with GPT and PPT performance in both ON (GPT: r = -0.48, PPT: r = 0.48) and OFF (GPT: r = -0.61, PPT: r = 0.45) states. Motor symptom severity in the OFF state showed moderate correlations with GPT (r = 0.48) and PPT (r = -0.58), but these associations were not significant in the ON phase (p > 0.05). Conclusion: Dopaminergic treatment improved motor symptoms, hand dexterity, and strength, without altering electrically induced contractile properties. Improved hand dexterity during treatment appears to be linked to strength gains independent of peripheral muscle changes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.